Affimed to Present at the LEERINK Partners Roundtable Series: Rare Disease & Immuno-Oncology

Heidelberg, Germany, September 22, 2017 - Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies, announced today that Dr. Adi Hoess, CEO, will present at the LEERINK Partners Roundtable Series: Rare Disease & Immuno-Oncology on Thursday, September 28, 2017 at 2:30 p.m. (ET) in New York City.

A live webcast of the conference presentation can be accessed through the "Events" section on the "Investors & Media" page of the Affimed website at http://www.affimed.com/events.php. A replay of the presentation will be available from Affimed's website for 30 days following the conference.

About Affimed N.V.

Affimed (Nasdaq: AFMD) engineers targeted immunotherapies, seeking to cure patients by harnessing the power of innate and adaptive immunity (NK and T cells). We are developing single and combination therapies to treat cancers and other life-threatening diseases. For more information, please visit www.affimed.com.

IR Contact:

Caroline Stewart, Head IRPhone: +1 347 394 6793 E-Mail: IR@affimed.com or c.stewart@affimed.com

Media Contact:

Anca Alexandru, Head of Communications, EU IRPhone: +49 6221 64793341E-Mail: a.alexandru@affimed.com

Affimed NV (NASDAQ:AFMD)
Historical Stock Chart
From Mar 2024 to Apr 2024